Kontakt 2006, 8(1):149-153 | DOI: 10.32725/kont.2006.025

Is ecstasy a dangerous drug?Biomedicine

Polák Robert
Jihočeská univerzita České Budějovice, Zdravotně sociální fakulta, katedra radiologie a toxikologie

Ecstasy, MDMA (3,4-methylenedioxymetamphetamine) is a synthetic, psychoactive substance, chemically similar to the stimulant metamphetamine and hallucinogen mescaline. MDMA exerts its effects particularly in the brain or in neurons, which use serotonin for their communication with other neurons. The serotonin system plays an important role in the control of the mood, aggressivity, sexual activity, sleep and sensitivity to the pain. The research on animals demonstrated that MDMA exerts neurotoxic effects; the question, if this also holds for man is currently being intensively studied. MDMA can be dangerous and it also can rarely cause the death. In high doses, MDMA disturbs the ability of the organism to control the body temperature. This can lead to a rapid increase in the body temperature (hyperthermia) with subsequent failures of the liver, kidney and cardiovascular systems. Thus, consumers of MDMA face the same danger as consumers of other stimulants, such as cocaine or amphetamines. They increase the heart frequency and blood pressure, which can be dangerous particularly for persons with circulation problems and myocardium diseases and they also induce further symptoms, such as muscular tone, twitching of teeth, vomiting, blurred vision, faints, tremor and sweating.

Keywords: Ecstasy; MDMA; metamphetamine; stimulant; hyperthemia; risk

Published: May 26, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Robert P. Is ecstasy a dangerous drug? Kontakt. 2006;8(1):149-153. doi: 10.32725/kont.2006.025.
Download citation

References

  1. BALTAROWICH, L., SMOLINSKE, S., THOMAS, R.: Fatal complications of ecstasy and amphetamine abuse. J. Toxicol. Clin. Toxicol. 2003. Vol. 41. s. 744.
  2. Benzenhofer, U., Passie, T.: The early history of "Ecstasy" [Article in German] Nervenarzt. [online]. 6/2006; [Epub ahead of print]
  3. DAVIS, W. M., HATOUM, H. T., WATERS, I. W.: Toxicity of MDA (3,4-methylenedioxyamphetamine) considered for relevance to hazards of MDMA (Ecstasy) abuse. Alcohol Drug Res. 1987. Vol. 7, s. 123-134.
  4. FIŠEROVÁ, M., PÁLENÍČEK, T.: MDMA (3,4-methylendioxymetamfetamin) - "extáze". Adiktologie. 2001. Vol. 2, s. 61-79.
  5. GABLE, R. S.: Acute toxic effects of club drugs. J. Psychoactive Drugs. 2004. Vol. 36, s. 303-313. Go to original source... Go to PubMed...
  6. HO, E., KARIMI-TABESH, L., KOREN, G.: Characteristics of pregnant women who use Ecstasy (3,4-methylenedioxymethamphetamine). Teratology. 2001. Vol. 63, s. 280. Go to original source... Go to PubMed...
  7. GOUZOULIS-MAYFRANK, E., DAUMANN, J.: The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J. Psychopharmacol. 2006. Vol. 20, s. 188-193. Go to original source... Go to PubMed...
  8. LU, H. et al.: Myocardial hypertrophy in users of methylenedioxymethamphetamine MDMA. J. Toxicol. Clin. Toxicol. 2003. Vol. 41, s. 693.
  9. LYLES, J., CAI, N. S., CADET, J. L.: Changes in gene expression induced by prenatal 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) exposure. FASEB J. 2003. Vol. 17, A1213.
  10. MEYER, J. S., GRANDE, M.: 3,4-Methylenedioxymethamphetamine (MDMA) increases cell death in the neonatal rat brain. Neurotoxicol. Teratol. 2003. Vol. 24, s. 421.
  11. MEYER, J. S., HSU, A.: Induction of the immediate-early gene Egr-1 by MDMA in neonatal rats. Neurotoxicol. Teratol. 2005. Vol. 27, s. 377-378.
  12. MILLER, D. B., O'CALLAGHAN, J. P.: Stress interactions with the neurotoxicity of the amphetamines. Neurotoxicko. Teratom. 1994. Vol.16, s. 327-328. Go to original source...
  13. MURPHY, P. N., WAREING, M., FISK, J.: Users' perceptions of the risks and effects of taking ecstasy (MDMA): a questionnaire study. J. Psychopharmacol. 2006. Vol. 20, s. 447-455. Go to original source... Go to PubMed...
  14. PATEL, M. M. et al.: Shedding new light on the "safe" club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad. Emerg. Med. 2004. Vol. 11, s. 208-210. Go to original source...
  15. PIPER, B. J. et al.: Analysis of the behavioral and neurochemical consequences of (+/-)3,4-methylenedioxymethamphetamine (MDMA or "ecstasy). Neurotoxicol. Teratol. 2005. Vol. 2 7, s. 377.
  16. SAUNDERS, N.: Extáze a Techno scéna, 1. vyd., Brno: JOTA, 1996. s. 314.
  17. SEGURA, M., FARRE, M., PICHINI, S. et al.: Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. Clin. Pharmacokinet. 2005. Vol. 44, s. 649-660. Go to original source... Go to PubMed...
  18. SMOLINSKE, S., BALTAROWICH, L., THOMAS R.: "Ecstasy? and methamphetamine related hyperthermia. Toxicol. Clin. Toxicol. 2003. Vol. 41, s. 655.
  19. SOKOL, M., FUSEK, J., NAVRÁTIL, P.: Omamné a psychotropní látky - metodologie profesních testů pro potřeby armády ČR. Voj. Zdrav. Listy. 2005. Vol. 74, s. 49-52.
  20. STICHT, G., PLUISCH, F., BIERHOFF, E., KAFERSTEIN, H.: Fatal outcome of Ecstasy overdose [Article in German] Arch. Kriminol. 2003. Vol. 211, s. 73-80.
  21. VANĚČEK, M.: Extáze. Bull. Nár. Protidrog. Centr. Praha, 1997. Vol. 1, s. 9-11.
  22. VAN TONNINGEN, M. R., GARBIS, H., REVERS, M. 1998: Ecstasy exposure during pregnancy. Teratology 58: 33A.
  23. VORHEES, C. V. et al.: Short-term effects of P11 MDMA treatment on monoamines, ACTH, corticosterone and serotonin transporter in rats. Neurotoxicol. Teratol. 2003. Vol. 25, s. 385-386.